December 15, 2016
NOXXON/Merck to study drugs combination in cancer treatment
NOXXON Pharma N.V. has announced a collaboration with Merck & Co. (MSD), Inc, under which the two companies will collaborate…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 15, 2016
Bioven gets green light for NSC cancer drug testing patient enrolment
A cancer-focused drug-maker Bioven can now enrol patients in the USA in its international Phase III trial of EGF-PTI, in…
December 15, 2016
Kiadis Pharma starts a P I/II clinical trial for thalassemia treatment
Kiadis Pharma N.V., a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders…
December 15, 2016
TiGenix raises $35.65M proceeds with NASDAQ IPO
A biopharmaceutical company TiGenix focused on allogeneic expanded stem cells, has raised $35.65 million gross proceeds from the sale of 2,300,000 American Depository…
December 15, 2016
Argenx launches P I/II clinical trial for acute myeloid leukemia treatment
Argenx, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe…
December 15, 2016
Pfizer/Astellas’s cancer drug study fails
Pfizer and Astellas Pharma have announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with…
December 15, 2016
Biocartis CE-marks Idylla NRAS-BRAF Mutation Test
Biocartis has CE-marked its solid biopsy Idylla NRAS-BRAF Mutation Test. On Thursday, Biocartis said that, together with the CE-marked Idylla…
December 15, 2016
PureTech health finishes tolerability testing of KarXT for schizophrenia and Alzheimer’s
Karuna Pharmaceuticals and a subsidiary of PureTech Health have finished studying antipsychotic for schizophrenia and Alzheimer’s disease – KarXT. The…
December 15, 2016
FDA nods to Pfizer’s skin disease drug
U.S. Food and Drug Administration (FDA) has approved Pfizer’s Eucrisa (crisaborole) ointment 2%, a novel non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor…
December 14, 2016
Horizon’s biomanufacturing business boosts revenue
Horizon Discovery Group has provided an update on the commercial operation of its Biomanufacturing business with significant growth in cell…